Search results
Bedside Manner Matters
Medscape· 3 hours ago"I've noticed there are certain types of doctors who are very intelligent but don't have that communication connection with patients," said Errol Ozdalga, MD, assistant professor ...
Fred Hutch announces eight recipients of 2024 Dr. | Newswise
Newswise· 6 days agoFred Hutch Cancer Center announced eight recipients of the national Dr. Eddie Méndez Scholar Award,...
Top Studies From ESOC 2024 in Review
Medscape· 5 days agoMedscape NeurologyDiener on NeurologyCOMMENTARYTop Studies From European Stroke Organisation Congress 2024 in ReviewHans-Christoph Diener, MD, PhD...
6 Things to Do in Your 30s to Improve Your Memory for the Long Haul
Self via Yahoo News· 7 days agoScott Turner, MD, PhD, director of the Memory Disorders Program at Georgetown University department...
Lifestyle Changes Still Net Benefits in OA, RA After 2 Years
Medscape· 6 days ago...European Alliance of Associations for Rheumatology (EULAR) 2024 Annual Meeting, Carlijn Wagenaar,...
Osteoarthritis Drugs Need Trials With Appropriate Endpoints
Medscape· 3 days agoFor the elusive target of disease-modifying OA drugs (DMOADs), "there have been a lot of...
Weakening sense of smell is linked to heart failure risk in a new study
MedicalNewsToday via AOL· 6 days agoLink between smell loss and heart failure surprising After reviewing this study, Cheng-Han Chen, MD,...
What Is Long COVID, Exactly? A New Universal Definition May Help More People Access Care
Health.com· 6 days ago“Our committee hopes this single definition, crafted with input from across research and patient...
Phase 3 Trial Supports Ixekizumab in Juvenile PsA, ERA
Medscape· 4 days agoWith a safety profile comparable with that seen in adult patients, ixekizumab "met the prespecified...
Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for...
Morningstar· 4 days agoGilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from an interim analysis of its pivotal, Phase 3 PURPOSE 1 trial indicating that the company’s twice-yearly injectable HIV ...
